The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Official Title: Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.
Study ID: NCT01648465
Brief Summary: The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens, , Greece
Dept of Medical Oncology, 251 General Airforce Hospital, Athens, , Greece
2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio", Athens, , Greece
2nd Dept of Internal Medicine, Propaedeutic, University Hospital "Attikon", Athens, , Greece
4th Dept of Internal Medicine, University Hospital "Attiko", Athens, , Greece
3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, , Greece
2nd Dept of Medical Oncology, Metropolitan Hospital, Athens, , Greece
Dept of Medical Oncology, University Hospital of Heraklion, Heraklion, , Greece
Dept of Medical Oncology, Ioannina University Hospital, Ioannina, , Greece
Division of Oncology, Dept of Internal Medicine, University Hospital of Patras, Patra, , Greece
Dept of Medical Oncology, Papageorgiou General Hospital, Thessaloniki, , Greece
Dept of Medical Oncology, Thermi Clinic, Thessaloniki, , Greece
Name: Anna Koumarianou, Dr
Affiliation: 4th Dept of Internal Medicine, University Hospital "Attikon"
Role: STUDY_CHAIR